*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Nnenna Finn
Advisor: Melissa L. Kemp
Abstract:
Doxorubicin is a well known chemotherapeutic agent used in the treatment of a variety of cancers. Previous research has identified most of the components that comprise the doxorubicin bioactivation network; however, adaptation of the network to changes in doxorubicin treatment or to patient-specific changes in network components is much less understood. We present a model of doxorubicin bioactivation in leukemia cells that illustrates the dual-nature of doxorubicin treatment, and highlights pharmacological intervention strategies for promoting or impeding doxorubicin-induced cytotoxicity in cancer cells.
